Related Experiment Video
Updated: Nov 1, 2025
07:16
Resin-Assisted Capture Coupled with Isobaric Tandem Mass Tag Labeling for Multiplexed Quantification of Protein Thiol Oxidation
Published on: June 21, 2021
1.9K
Interfering with the Reactive Cysteine Proteome in COVID-19
1Department of Pathology, Lluis Alcanyis Hospital, Xátiva, Valencia, Spain.
Current Medicinal Chemistry
|June 24, 2021
Summary
Repurposed FDA-approved drugs show promise for treating severe COVID-19 by targeting viral proteins and host cysteine proteome. These safe therapies may suppress the virus while modulating the immune response.
Area of Science:
- Virology
- Drug Repurposing
- Immunology
Background:
- Vaccination for SARS-CoV-2 is ongoing, but effective treatments for severe COVID-19 remain critical.
- Viral proteins significantly influence the progression of severe COVID-19 disease.
Purpose of the Study:
- To explore the potential of FDA-approved drugs as therapies for severe COVID-19.
- To investigate how these drugs interfere with viral proteins and the host's cysteine proteome.
Main Methods:
- Literature review of existing studies on drug repurposing for COVID-19.
- Analysis of the biological mechanisms of clinically safe drugs targeting viral cysteine proteases.
Main Results:
- Certain FDA-approved drugs demonstrate the ability to inhibit the SARS-CoV-2 life cycle.
- These drugs may modulate the host's inflammatory and immune responses by interacting with the cysteine proteome.
Conclusions:
- Repurposing clinically safe drugs offers a viable therapeutic strategy for severe COVID-19.
- Targeting viral cysteine proteases and host cysteine proteome could be key to effective COVID-19 treatment.
Related Concept Videos
01:13The Proteasome
1.3K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.3K
02:18The Proteasome
9.3K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
9.3K
01:23Cystic Fibrosis: Pathogenesis
481
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
481
01:37The Unfolded Protein Response
5.6K
The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
5.6K